Neurocrine Biosciences, Inc. (NBIX) Posts Q3 EPS of $0.56, Revenues Rose 189% Y/Y
Neurocrine Biosciences, Inc. (NASDAQ: NBIX) reported Q3 EPS of $0.56, which may not compare to the analyst estimate of $0.19. Revenue for the quarter came in at $41.6 million versus the consensus estimate of $21.64 million.